Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 million in June, management is pushing ahead with plans to find partners ...

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has ...

The president and CEO of Imunon Inc. has resigned “to pursue another business opportunity,” the Lawrenceville-based biotechnology company announced March 12. Corinne Le Goff’s resignation is effective ...

IMUNON announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 60,000 shares of the Company’s common stock ...

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian cancer. The results showed that when given to women recently diagnosed ...

Imunon shares are trading lower by 61% during Wednesday's session. The company announced a $10 million registered direct offering. Up Next: Wall Street trader’s 34-0 strategy goes public this week.

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , ...

LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock ...

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, ...

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses ...